RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Corcept Therapeutics Stock

Corcept Therapeutics Net Income 2025

Corcept Therapeutics Net Income

138.03 M USD

Ticker

CORT

ISIN

US2183521028

WKN

529882

In 2025, Corcept Therapeutics's profit amounted to 138.03 M USD, a -2.25% increase from the 141.21 M USD profit recorded in the previous year.

The Corcept Therapeutics Net Income history

YEARNET INCOME (B USD)
2030e1.5
2029e1.25
2028e0.99
2027e0.65
2026e0.28
2025e0.14
20240.14
20230.11
20220.1
20210.11
20200.11
20190.09
20180.08
20170.13
20160.01
2015-0.01
2014-0.03
2013-0.05
2012-0.04
2011-0.03
2010-0.03
2009-0.02
2008-0.02
2007-0.01
2006-0.02
2005-0.02

Corcept Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Corcept Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Corcept Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Corcept Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Corcept Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Corcept Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Corcept Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Corcept Therapeutics’s growth potential.

Corcept Therapeutics Revenue, EBIT and net profit per share

DateCorcept Therapeutics RevenueCorcept Therapeutics EBITCorcept Therapeutics Net Income
2030e3.12 B undefined0 undefined1.5 B undefined
2029e2.71 B undefined1.76 B undefined1.25 B undefined
2028e2.29 B undefined1.38 B undefined985.41 M undefined
2027e1.6 B undefined874.32 M undefined648.58 M undefined
2026e1.21 B undefined358.19 M undefined279.25 M undefined
2025e881.74 M undefined116.61 M undefined138.03 M undefined
2024675.04 M undefined136.95 M undefined141.21 M undefined
2023482.38 M undefined107.28 M undefined106.14 M undefined
2022401.9 M undefined112.6 M undefined101.4 M undefined
2021366 M undefined124.5 M undefined112.5 M undefined
2020353.9 M undefined128.2 M undefined106 M undefined
2019306.5 M undefined111.6 M undefined94.2 M undefined
2018251.2 M undefined89.5 M undefined75.4 M undefined
2017159.2 M undefined52.9 M undefined129.1 M undefined
201681.3 M undefined10.2 M undefined8.1 M undefined
201550.3 M undefined-3.4 M undefined-6.4 M undefined
201426.6 M undefined-27.6 M undefined-31.4 M undefined
201310.4 M undefined-41.5 M undefined-46 M undefined
20123.3 M undefined-36.3 M undefined-38 M undefined
20110 undefined-32.3 M undefined-32.4 M undefined
20100 undefined-27.5 M undefined-26 M undefined
20090 undefined-20.3 M undefined-20.2 M undefined
2008200,000 undefined-19.7 M undefined-20.1 M undefined
2007500,000 undefined-12.2 M undefined-11.6 M undefined
2006300,000 undefined-25.6 M undefined-24.9 M undefined
20050 undefined-21.2 M undefined-20.1 M undefined

Corcept Therapeutics stock margins

The Corcept Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Corcept Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Corcept Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Corcept Therapeutics's sales revenue. A higher gross margin percentage indicates that the Corcept Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Corcept Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Corcept Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Corcept Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Corcept Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Corcept Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Corcept Therapeutics Margin History

Corcept Therapeutics Gross marginCorcept Therapeutics Profit marginCorcept Therapeutics EBIT marginCorcept Therapeutics Profit margin
2030e98.39 %0 %47.95 %
2029e98.39 %64.76 %46.13 %
2028e98.39 %60.03 %42.99 %
2027e98.39 %54.68 %40.56 %
2026e98.39 %29.5 %23 %
2025e98.39 %13.22 %15.65 %
202498.39 %20.29 %20.92 %
202398.66 %22.24 %22 %
202298.66 %28.02 %25.23 %
202198.55 %34.02 %30.74 %
202098.42 %36.22 %29.95 %
201998.21 %36.41 %30.73 %
201897.93 %35.63 %30.02 %
201797.74 %33.23 %81.09 %
201697.54 %12.55 %9.96 %
201597.22 %-6.76 %-12.72 %
201496.62 %-103.76 %-118.05 %
201398.08 %-399.04 %-442.31 %
201296.97 %-1,100 %-1,151.52 %
201198.39 %0 %0 %
201098.39 %0 %0 %
200998.39 %0 %0 %
200898.39 %-9,850 %-10,050 %
200798.39 %-2,440 %-2,320 %
200698.39 %-8,533.33 %-8,300 %
200598.39 %0 %0 %

Corcept Therapeutics Aktienanalyse

What does Corcept Therapeutics do?

Corcept Therapeutics Inc is a biopharmaceutical company specializing in the development of drugs for the treatment of metabolic, hormonal, and cancer-related diseases. The company was founded in 1998 by Dr. Joseph Belanoff, who still serves as the Chief Executive Officer. The history of Corcept Therapeutics is closely linked to the discovery of mifepristone, a drug that acts as an antagonist to cortisol receptors. In 2002, the company acquired the rights to mifepristone from Roussel Uclaf, a subsidiary of Hoechst AG, and developed it into the drug Korlym (mifepristone). Korlym was approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of patients with endogenous Cushing's syndrome, a severe hormone disorder. The core business of Corcept Therapeutics is the research and development of drugs that affect the body's hormonal balance. In addition to Korlym, the company has also brought other innovative drugs to the market aimed at alleviating or even curing the symptoms of hormonal disorders. These drugs include relacorilant, which is currently undergoing Phase III studies for the treatment of patients with Cushing's syndrome. Another division of Corcept Therapeutics is the development of drugs for the treatment of cancer. The company has conducted several clinical trials to test the efficacy of its drug Korlym in treating certain types of cancer, including breast cancer, lung cancer, and prostate cancer. More recently, Corcept Therapeutics has also developed a new drug called Exicure, which focuses on the treatment of liver cancer. Overall, Corcept Therapeutics has built a wide portfolio of products and services targeting patients with different medical needs. The company has also formed partnerships with other companies and research institutes to support its research and development efforts and improve access to its products. The business model of Corcept Therapeutics is based on partnerships with physicians, hospitals, and clinics that utilize its products and services to help patients with metabolic, hormonal, and cancer-related diseases. The company also relies on close collaboration with the FDA and other regulatory agencies to ensure that its drugs meet the highest standards of safety and efficacy. Corcept Therapeutics is headquartered in Menlo Park, California, USA, and currently employs around 250 people. The company has experienced strong growth in recent years, both through the development of new products and the expansion of its business into global markets. In summary, Corcept Therapeutics Inc is a leading biopharmaceutical company specializing in the development of drugs for the treatment of hormone, metabolic, and cancer-related diseases. With its broad portfolio of innovative products and services, the company has made a significant contribution to improving the health and well-being of millions of people worldwide. Corcept Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Corcept Therapeutics's Profit Margins

The profit margins of Corcept Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Corcept Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Corcept Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Corcept Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Corcept Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Corcept Therapeutics stock

How much profit has Corcept Therapeutics made this year?

Corcept Therapeutics has made 138.03 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -2.25% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Corcept Therapeutics publish its earnings?

Corcept Therapeutics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Corcept Therapeutics?

The profits of Corcept Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Corcept Therapeutics?

You can learn more about the earnings of Corcept Therapeutics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Corcept Therapeutics pay?

Over the past 12 months, Corcept Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Corcept Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Corcept Therapeutics?

The current dividend yield of Corcept Therapeutics is .

When does Corcept Therapeutics pay dividends?

Corcept Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Corcept Therapeutics?

Corcept Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Corcept Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Corcept Therapeutics located?

Corcept Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Corcept Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Corcept Therapeutics from 8/25/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/25/2025.

When did Corcept Therapeutics pay the last dividend?

The last dividend was paid out on 8/25/2025.

What was the dividend of Corcept Therapeutics in the year 2024?

In the year 2024, Corcept Therapeutics distributed 0 USD as dividends.

In which currency does Corcept Therapeutics pay out the dividend?

The dividends of Corcept Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Corcept Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Corcept Therapeutics

Our stock analysis for Corcept Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Corcept Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.